KUALA LUMPUR, April 24 (Bernama) -- Aptorum Group Limited has established a new subsidiary group, Smart Pharma (SmartP), which operates its novel computational repurposed drug discovery, modelling and validation platform, together referred to as the Smart-ACT™ platform.
Smart-ACT™ stands for Accelerated Commercialization of Therapeutics and encompasses state-of-the-art technology in systematic screening of existing approved drug molecules against selected therapeutic targets.
Specifically, the platform comprises a network of modules and processes that simulates the effectiveness of drug molecules against diseases for outcome prediction and selection.
It will initially focus on screening drug molecules for orphan diseases or unmet medical needs.
To date, SmartP has successfully screened 1,615 compounds against three therapeutic target proteins which are related to poor prognosis of neuroblastoma (NB).
NB is a cancer that forms in certain types of nerve tissue and most frequently, in the adrenal glands as well as spine, chest, abdomen or neck.
The preliminary results from the Smart-ACT™ platform have now identified a number of potential repurposed drug candidates that could show promise against such disease.
SmartP will next move on to conduct further in vitro and in vivo validation of these candidates through collaboration with Aptorum Group Limited to assess and validate the candidates’ usage for such new indication.
SmartP targets to discover up to 10 repurposed drug candidates per annum under the Smart-ACT™ platform, which will continue to develop and enrich its library of intellectual property for such discoveries.
Further information on the Smart-ACT™ platform at http://www.smtph.com
-- BERNAMA
No comments:
Post a Comment